Pedro de Marchi | Epidemiology | Academic Engagement Excellence Award

Posted on by ScienceFather

Dr. Pedro de Marchi | Epidemiology | Academic Engagement Excellence Award

Dr. Pedro de Marchi, ONCOCLINICAS, Brazil

Dr. Pedro de Marchi is a leading medical oncologist specializing in head and neck cancer at Oncoclínicas, Brazil. He serves as the National Leader and Medical Coordinator, alongside being a Professor of Medicine at Universidade Estadual do Rio de Janeiro. Dr. Marchi completed his MD at Universidade Federal de Santa Maria and furthered his training in internal medicine and oncology. His research focuses on the efficacy of immune checkpoint inhibitors and head and neck squamous cell carcinoma. Dr. Marchi has led several significant studies and has been involved in numerous conferences to advance cancer treatment. 🎗️👨‍⚕️📚

Publication Profile

Google Scholar

Education

Dr. Pedro de Marchi earned his MD from Universidade Federal de Santa Maria (UFSM) in 2008. He completed a residency in Internal Medicine at the Universidade Federal do Rio Grande do Sul and a Clinical Fellowship in Medical Oncology at Hospital São Lucas (PUC-RS). He further enriched his expertise through an observership at The University of Texas MD Anderson Cancer Center. Dr. Marchi holds a Master’s in Oncology from Fundação Pio XII, focusing on chemotherapy toxicity in head and neck cancer, and a PhD in Oncology, studying immune checkpoint inhibitors and biomarkers in lung cancer. 🎓💉📖

 

Experience and Service

Dr. Pedro de Marchi has an extensive career in oncology, serving as a resident at Universidade Federal do Rio Grande do Sul (2009-2011) and a Medical Oncology Fellow at Hospital São Lucas (2011-2014). He was the Head of Thoracic and Head & Neck Oncology at Barretos Cancer Hospital (2016-2020) and is currently a National Leader in Head & Neck Cancer at Oncoclínicas. In addition, he coordinates multiple fellowship programs and serves as a Professor of Medicine at Universidade Estadual do Rio de Janeiro. His leadership roles reflect his commitment to advancing oncology care and research. 🩺🌟📚

 

Honors and Awards

Dr. Pedro de Marchi was recognized with the AMRIGS Medical Qualification by the Medical Association of Rio Grande do Sul in Porto Alegre, Brazil, in 2008. This prestigious honor highlights his dedication to the medical field and his commitment to achieving excellence in healthcare. The award underscores his professional qualifications and serves as a testament to his skills as a medical practitioner. Dr. de Marchi’s achievements reflect his continuous pursuit of knowledge and his contribution to advancing medical practice in Brazil. 🏆🎓🌟

 

Research Contributions

Dr. Pedro de Marchi has made significant contributions to cancer research through various grants and contracts. As the Principal Investigator, he led studies on head and neck squamous cell carcinoma epidemiology and COVID-19 mortality determinants among cancer patients, securing substantial funding from notable organizations like MSD, AMGEN, and AstraZeneca. His research includes pivotal Phase III trials assessing innovative treatments for squamous cell carcinoma. These efforts not only advance medical knowledge but also aim to improve patient outcomes in Brazil. Dr. de Marchi’s work is essential in addressing critical health challenges in oncology. 📊🔬🎗️

 

Teaching

Dr. Pedro de Marchi plays a vital role in medical education and mentorship. He serves as a Clinical Research Mentor in the Oncoclinicas Mentorship Programme since 2024, fostering the next generation of oncologists. As a Professor at Universidade Estadual do Rio de Janeiro (UERJ), he instructs rotating medical students, enhancing their clinical skills. Additionally, Dr. de Marchi supervises postdoctoral research fellows in Internal Medicine and Thoracic and Head & Neck Medical Oncology, guiding them in their academic and clinical pursuits. His commitment to education ensures that future physicians are well-equipped for the challenges of oncology. 📚👨‍⚕️🎓

 

Conclusion

Dr. Pedro de Marchi exemplifies the qualities sought after for the Research for Academic Engagement Excellence Award. His leadership in cancer research, dedication to education, and significant contributions to the field make him a suitable candidate for this prestigious recognition.

Publication Top Notes

  • Pembrolizumab versus chemotherapy for untreated PD-L1-expressing NSCLC (KEYNOTE-042) 🌟 — Cited by: 3065, Year: 2019
  • Durvalumab plus platinum–etoposide for extensive-stage SCLC (CASPIAN) 🎯 — Cited by: 1679, Year: 2019
  • First-line nivolumab plus ipilimumab and chemotherapy in NSCLC (CheckMate 9LA) 🚀 — Cited by: 1086, Year: 2021
  • Durvalumab with/without tremelimumab for extensive-stage SCLC (CASPIAN) ⚖️ — Cited by: 487, Year: 2021
  • CheckMate 9LA 2-year update: nivolumab plus ipilimumab and chemotherapy vs. chemotherapy alone 🕒 — Cited by: 172, Year: 2021
  • Lung cancer in Brazil 🇧🇷 — Cited by: 142, Year: 2018
  • PD-L1 expression in NSCLC: TPS vs. CPS 🧬 — Cited by: 77, Year: 2021
  • Câncer de pulmão no Brasil 📈 — Cited by: 70, Year: 2018
  • MiR-21 as a prognostic biomarker in head and neck SCC 📊 — Cited by: 69, Year: 2017
  • Determinants of COVID-19 mortality in cancer patients in Brazil 🦠 — Cited by: 50, Year: 2021

Naveen Khargekar | Public Health Award | Best Researcher Award

Posted on by ScienceFather

Dr. Naveen Khargekar | Public Health Award | Best Researcher Award

Dr. Naveen Khargekar, ICMR-National Institute of Immunohaematology, India

Based on Dr. Naveen Khargekar’s extensive qualifications and achievements, he appears to be a strong candidate for the Research for Best Researcher Award. Here’s a detailed evaluation:

Publication profile

Education

Dr. Khargekar holds an MD in Community Medicine from Topiwala National Medical College, Mumbai, with a thesis focused on protein energy malnutrition in tribal areas. He further specialized in Preventive Oncology through a fellowship at Homi Bhabha National Institute, Tata Memorial Center. His UICC Technical Fellowship provided individual mentorship in cervical cancer, enhancing his expertise in cancer prevention and treatment.

Employments

Dr. Khargekar’s career includes significant roles such as Scientist-E at ICMR-National Institute of Immunohaematology, Assistant Professor in Preventive Oncology at Tata Memorial Center, and Consultant & Coordinator at Sri Shankara Cancer Hospital. His work demonstrates a strong commitment to cancer research and community oncology.

Teaching Activities

Dr. Khargekar has been involved in various educational initiatives, including workshops on tobacco control, preventive oncology, and sickle cell disease. His contributions to CME programs and residential workshops highlight his dedication to training and capacity building in the field of community and preventive medicine.

Workshops and Seminars

Dr. Khargekar’s participation in numerous workshops and seminars, including those on research methodology, good clinical practices, and systematic reviews, reflects his commitment to staying updated with the latest advancements and methodologies in research and public health.

Publication Top Notes

  1. Knowledge, attitude, and practice about cervical cancer and its screening among community healthcare workers of Varanasi district, Uttar Pradesh, India
    D Khanna, N Khargekar, A Budukh
    Journal of Family Medicine and Primary Care 8 (5), 1715-1719
    Cited by: 68 (2019) 🩺
  2. Compliance of cigarettes and other tobacco products act among tobacco vendors, educational institutions, and public places in Bengaluru City
    NC Khargekar, A Debnath, NR Khargekar, P Shetty, V Khargekar
    Indian Journal of Medical and Paediatric Oncology 39 (04), 463-466
    Cited by: 25 (2018) 🚭
  3. Immunization status of children under 5 years in a tribal area, Parol, Thane district
    NC Khargekar, VC Khargekar, PP Shingade
    National Journal of Community Medicine 6 (04), 522-527
    Cited by: 23 (2015) 💉
  4. Determinants of tobacco use and prevalence of oral precancerous lesions in cab drivers in Bengaluru City, India
    P Shetty, NC Khargekar, A Debnath, NR Khargekar, BK Srivastava
    International Journal of Preventive Medicine 8 (1), 100
    Cited by: 18 (2017) 🚬
  5. Role of social support in tobacco cessation
    N Khargekar
    International Journal of Community Medicine and Public Health 4 (11), 3942
    Cited by: 15 (2017) 💪
  6. Implementation of early detection services for cancer in India during COVID-19 pandemic
    D Khanna, NC Khargekar, AK Khanna
    Cancer Control 27 (1), 1073274820960471
    Cited by: 12 (2020) 🦠
  7. Cancer pattern in Varanasi district from Uttar Pradesh state of India, a foundation for cancer control based on the first report of the population-based cancer registry
    AM Budukh, S Pradhan, VB Singh, D Khanna, SS Bagal, PS Chakravarti
    Indian Journal of Cancer
    Cited by: 11 (2023) 🎗️
  8. A cross-sectional study to assess the protein energy malnutrition in children between one to five years of age in a tribal area Parol, Thane district, Maharashtra, India
    NC Khargekar, VC Khargekar, PP Shingade
    International Journal of Community Medical Public Health 3, 112-120
    Cited by: 8 (2016) 🍽️
  9. Cleft lip and palate-A psychology insight
    N Khargekar, N Khargekar, V Khargekar, S Rajan
    Sci Publ Group 5 (4), 37
    Cited by: 6 (2016) 👄
  10. Chronic Hepatitis B and Related Liver Diseases Are Associated with Reduced 25-Hydroxy-Vitamin D Levels: A Systematic Review and Meta-Analysis
    A Banerjee, S Athalye, N Khargekar, P Shingade, M Madkaikar
    Biomedicines 11 (1), 135
    Cited by: 5 (2023) 🦠
  11. Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis
    N Khargekar, A Banerjee, S Athalye, N Mahajan, N Kargutkar, P Tapase
    Systematic Reviews 13 (1), 60
    Cited by: 4 (2024) 💊
  12. Exploring risk factors and transmission dynamics of Hepatitis B infection among Indian families: Implications and perspective
    S Athalye, N Khargekar, S Shinde, T Parmar, S Chavan, G Swamidurai
    Journal of Infection and Public Health 16 (7), 1109-1114
    Cited by: 4 (2023) 🦠
  13. A systematic review on hydroxyurea therapy for sickle cell disease in India
    A Pandey, H Kaur, S Borah, N Khargekar, VK Karra, T Adhikari, D Jain
    Indian Journal of Medical Research 156 (2), 299-311
    Cited by: 4 (2022) 💉
  14. A cross sectional assessment of the profile of risk factors of non-communicable diseases among health care staff of a tertiary cancer hospital
    N Khargekar, A Singh, T Shruti, S Pradhan
    Journal of Lifestyle Medicine 12 (2), 98
    Cited by: 4 (2022) 🏥
  15. Comparative study of clinical features and vaccination status in Omicron and non-Omicron infected patients during the third wave in Mumbai, India
    A Takke, M Zarekar, V Muthuraman, A Ashar, K Patil, A Badhavkar
    Journal of Family Medicine and Primary Care 11 (10), 6135-6142
    Cited by: 3 (2022) 🦠
  16. Is it possible to reduce cancer burden in India
    N Khargekar, V Khargekar, HG Srivatsa, N Khargekar
    J Med Sci Clin Res 5, 19837-44
    Cited by: 3 (2017) 🇮🇳
  17. Cancer Screening during COVID-19 Pandemic
    NC Khargekar, D Khanna
    Asia-Pacific Journal of Oncology Nursing 7 (4), 308-309
    Cited by: 2 (2020) 🦠
  18. Exploring factors influencing the perspective regarding HIV transmission and prevention among college students in India
    N Khargekar, A Takke, S Athalye, P Panale, N Rajamani, A Banerjee
    Journal of Family Medicine and Primary Care 13 (4), 1467-1472
    Cited by: 1 (2024) 🧬
  19. Impact of COVID-19 infection among Indian sickle cell disease patients
    N Khargekar, N Shinde, A Banerjee, M Madkaikar, A Nadkarni
    Indian Journal of Public Health 67 (1), 112-116
    Cited by: 1 (2023) 🦠
  20. Epidemiological study of adverse events following immunization in under 5 year children
    VS Pagar, SS Chavan, SP Patil, A Borde, AD Kinge, N Khargekar
    Journal of Family Medicine and Primary Care 10 (7), 2482-2487
    Cited by: 1 (2021) 💉

Conferences and Presentations

He has actively participated in national and international conferences, presenting papers on topics such as cancer screening compliance and hematological parameters in sickle cell anemia patients. His engagement in these forums demonstrates his active role in advancing medical knowledge and practices.

Achievements

Dr. Khargekar is a member of several institutional committees, including ethics and biosafety committees, which indicates his involvement in maintaining high standards of research ethics and safety.

Conclusion

Dr. Naveen Khargekar’s extensive education, diverse experience, active involvement in teaching and research, and significant contributions to peer-reviewed literature position him as a highly suitable candidate for the Research for Best Researcher Award. His work in preventive oncology and public health aligns well with the criteria for this prestigious award.